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Abstract 
 
Background: Alzheimer pathogenesis has been associated with a network of processes working 
simultaneously and synergistically. Over time, much interest has been focused on cholinergic transmission 
and its mutual interconnections with other active players of the disease. Besides the cholinesterase mainstay, 
the multifaceted interplay between nicotinic receptors and amyloid is actually considered to have a central 
role in neuroprotection. Thus, the multitarget drug-design strategy has emerged as a chance to face the 
disease network. Results: By exploiting the multitarget approach, the present study provides new molecules 
able to target the cholinergic pathway, by joining direct nicotinic receptor stimulation to acetylcholinesterase 
inhibition, and to inhibit Aβ aggregation. Conclusions: These new compounds emerged as a suitable starting 
point for a further optimization process. 
 
Keywords: Alzheimer’s disease, Nicotinic receptors, Acetylcholinesterase inhibitors, Multitarget 
compounds, Amyloid aggregation.   
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Introduction 
Research into treatments for Alzheimer’s disease (AD), the most common form of dementia that imparts a 
slow progression of cognitive decline, and ultimately death, has yet to yield to a substantial improvement in 
cure or prevention [1]. One of the major obstacles in developing effective drug therapies has been the lack of 
a single model that can adequately mimic all signs of the disease and, consequently, of a comprehensive 
hypothesis able to clarify the interconnected mechanisms behind the histopathological changes observed in 
AD patients. What is clear to date is that AD has a multifactorial nature, where multiple biological and 
genetic factors coexist [2]. In this complex scenario, two neurochemical defects have been almost universally 
described as occurring during the mild to moderate phase: cholinergic neuronal loss and beta-amyloid (Aβ) 
peptide misfolding and aggregation [3]. 
In the last decades, the cholinergic hypothesis has inspired the first-line treatment for AD. In particular, three 
of the four drugs currently approved by the US FDA (i.e. donepezil, rivastigmine, and galantamine) are 
directed towards temporary enhancing acetylcholine (ACh)-dependent neurotransmission through the 
inhibition of the enzyme acetylcholinesterase (AChE). ACh levels can also be restored in the short term by 
the inhibition of butyrylcholinesterase (BChE), whose concentration gradually increases in advancing AD, 
while AChE activity declines [4, 5]. Besides the cholinesterase (ChE) mainstay, much interest has also been 
directed to the modulation of neuronal nicotinic receptor (nAChR) activity [6]. In addition to their 
involvement in the cholinergic transmission, nAChRs are considered to play important roles in 
neuroprotection [7]. Several agonists of both  and 7 nAChRs have reached clinical evaluation in 
patients with mild to moderate AD, demonstrating safety, tolerability, and positive effects across multiple 
cognitive domains [8]. There is in fact the consensus view that activation of nAChRs protects neurons from 
Aβ toxicity [9], and that Aβ and its oligomers target neurons at least partly via nAChRs, sorting different 
effects ranging from synaptic potentiation to inhibition of neurotransmitter release, according to the peptide 
concentration [10]. In particular, physiological concentrations of Aβ may directly stimulate nAChRs, 
while at increasing Aβ levels, in a pathological context, it impairs the cholinergic responses mediated by 
both 7 and  receptors [3]. To corroborate the Aβ-nAChR correlation, some studies have also confirmed 
that activation of nAChRs contributes to decreased Aβ generation by modulating the amyloid precursor 
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protein (APP) processing [3], protecting neurons from the peptide toxicity. Therefore, the amyloidogenic and 
cholinergic pathways, while being considered independent for years, share a number of molecular features 
that merge at several points. This intertwined correlation is part of a complex network of A-centred 
pathogenic events that may possibly account for the failure hitherto encountered with purely anti-amyloid 
strategies. 
 
 
 
 
Figure 1. Rational Design of 1-5. 
 
 
In this scenario, we envisaged the development of multitarget compounds, i.e. small molecules able to 
simultaneously address multiple targets critically involved in the AD network [11-13], as a promising 
therapeutic choice. In particular, we sought to exploit the abovementioned mutual interactions between Aβ 
and cholinergic transmission by endowing singular chemical entities of both antiaggregating ability and 
cholinergic properties (i.e. AChE inhibition and nAChR activation). To this end, we followed a ligand-based 
approach and combined synergistic pharmacophores into chimera compounds 1-5 by linking a 1-(2-
methoxybenzyl)-piperazine function to a carbazole moiety through different length spacers. Substituted 
carbazoles have shown to exert anti-amyloidogenic activity [14], and to interact with the AChE gorge 
(Figure 1)[15]. The selection of the 1-(2-methoxybenzyl)-piperazine function was based on the structural 
similarity between the ethyl-(2-methoxybenzyl)-amine group, that was already proven effective in 
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recognizing the AChE catalytic site [16, 17], and the 1-(2,4-dimethoxyphenyl)-piperazine moiety, which 
demonstrated leading properties for 7 nAChR activation [18].  
 
Materials & methods 
Chemistry. Melting points were taken in glass capillary tubes on Buchi SMP-20 apparatus and are 
uncorrected. IR, electron impact (EI) mass, and direct infusion ESI-MS spectra were recorded on Perkin-
Elmer 297, VG 7070E, and Waters ZQ 4000 apparatus, respectively. 1H and 13C NMR spectra were recorded 
on Varian VXR 200, 300 and 400 instruments. Chemical shifts are reported in parts per millions (ppm) 
relative to tetramethylsilane (TMS), and spin multiplicities are given as s (singlet), br s (broad singlet), d 
(doublet), t (triplet), or m (multiplet). Chromatographic separations were performed on silica gel columns by 
flash (Kieselgel 40, 0.040-0.063 mm; Merck) chromatography. Reactions were followed by thin-layer 
chromatography (TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates (60 F254), then 
visualized in an iodine chamber or with an UV lamp.  
Synthesis of 4-(7-Bromoeptyloxy)-9H-carbazole (11). It was synthesised according to Rosini et al.[15]: 
1,7-dibromoheptane (8.19 mmol, 3 equiv) and catalytic amount of KI were added to a solution of 4-
hydroxycarbazole (6) (0.500 g, 2.73 mmol, 1 equiv) and powdered KOH (0.153 g, 2.73 mmol, 1 equiv) in 
CH3CN (25 mL). After stirring at room temperature for 12 h, the solvent was removed under vacuum, 
affording an oily residue that was purified by flash chromatography. Elution with CH2Cl2/petroleum ether 
(3.5:6.5) afforded 11 as a white solid: 57% yield; mp 84-86 °C; 1H NMR (200 MHz, CDCl3) δ 1.37-2.16 (m, 
10H), 3.37 (t, J = 7.0 Hz, 2H), 4.41 (t, J = 6.8 Hz, 2H), 6.72-6.76 (m, 1H), 7.00-7.14 (m, 1H), 7.29-7.53 (m, 
4H), 8.10 (br s, 1H exchangeable with D2O), 8.42 (d, J = 8 Hz, 1H). 
1-(2-Methoxy-benzyl)-piperazine (12). 1-Cloromethyl-2-methoxy-benzene (0.3 mL, 2.13 mmol, 1 eq) was 
added dropwise to a solution of piperazine (1.85 g, 21.6 mmol, 10 eq) and K2CO3 (0.55 g, 3.97mmol, 2 eq) 
in dry DMF (15 mL). The reaction mixture allowed to stir at rt. After 24 h, the mixture was warmed up to 70 
ºC for 4 h and the solvent was then evaporated. A solution of KHSO4 was added to the crude product and 
extracted with CH2Cl2. The acidic solution was made basic with KOH and extracted again with CH2Cl2; the 
combined extract layers were dried and evaporated to give 12: 95% yield; 1H NMR (300 MHz, CDCl3) δ 
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2.27-2.37 (m, 4H), 2.65-2.70 (m, 4H), 3.37 (s, 2H), 3.60 (s, 3H), 6.66 (d, J = 7.8 Hz, 1H), 6.74 (t, J = 7.5 Hz, 
1H), 7.03 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 7.8 Hz, 1H), 7.79 (br s, 1H exchangeable with D2O). 
General procedure for the synthesis of 1-5. The appropriate bromide (1.02 mmol, 1 equiv) and a catalytic 
amount of KI were added to a solution of 12 (0.21 g, 1.02 mmol, 1 equiv) and powdered K2CO3 (0.14 g, 1.02 
mmol, 1 equiv) in dry DMF (5 mL). After stirring under N2 atmosphere for 6 h at 70 ºC, the solvent was 
removed under vacuum, affording a residue that was purified by flash chromatography.  
4-{3-[4-(2-Methoxy-benzyl)-piperazin-1-yl]-propoxy}-9H-carbazole (1). It was synthesized from 7 [15] 
(0.31g, 1.02 mmol) and purified by flash chromatography. Elution with a gradient system petroleum 
ether/ethyl acetate/EtOH (from 6.1:3.8:0.7 to 6.4:3.8:0.7 to 6.6:3.8:0.7 ) afforded 1 as a solid: 54%yield; mp 
97-99 ºC; 1H NMR (400 MHz, CDCl3) δ 1.37-1.39 (m, 2H), 2.13-2.17 (m, 2H), 2.63-2.71 (m, 8H), 3.65 (s, 
2H), 3.77 (s, 3H), 4.22 (t, J = 6.6 Hz, 2H), 6.61 (d, J = 8.2 Hz, 1H), 6.84 (d, J = 8 Hz, 1H), 6.90-6.94 (m, 
1H), 6.98 (d, J = 8.2 Hz, 1H), 7.17-7.33 (m, 6H), 8.25 (d, J = 8 Hz, 1H), 8.39 (br s, 1H exchangeable with 
D2O). 13C NMR (100 MHz, CDCl3) δ 26.83, 52.62 (2C), 52.95, 55.37, 55.46 (2C), 55.83, 66.14, 100.91, 
103.46, 109.97, 110.49, 112.54, 119.49, 120.34, 122.61, 122.91 (2C), 124.82, 126.58, 128.45, 131.01, 
138.71, 140.94, 155.46, 157.89. MS (ESI+): m/z 430 [M+H]+. 
4-{4-[4-(2-Methoxy-benzyl)-piperazin-1-yl]-butoxy}-9H-carbazole (2). It was synthesized from 8 [15] 
(0.32 g, 1.02 mmol) and purified by flash chromatography. Elution with a gradient system from petroleum 
ether/ethyl acetate/EtOH (5.5:4.0:0.05) to petroleum ether/ethyl acetate/EtOH/ ammonia solution 30 % (from 
6.1:3.8:0.1:0 to 6.1:3.8:0.1:0.001), afforded 2 as a solid: yield 46 %; 1H NMR (200 MHz, CDCl3) δ 1.18-1.39 
(m, 2H), 1.82-1.86 (m, 2H), 1.95-2.05 (m, 2H), 2.47-2.61 (m, 8H), 3.65 (s, 2H), 3.79 (s, 3H), 4.24 (t, J = 6.2 
Hz, 2H), 6.66 (d, J = 7.8 Hz, 1H), 6.85-7.02 (m, 3H), 7.24-7.38 (m, 6H), 8.33 (d, J = 7.8 Hz, 1H), 8.56 (br s, 
1H exchangeable with D2O). 13C NMR (100 MHz, CDCl3) δ 25.65, 27.30, 51.42 (2C), 52.36, 54.24, 54.96 
(2C), 55.03, 66.00, 101.03, 102.94, 108.87, 109.69, 111.34, 118.65, 119.34, 121.31, 122.36, 122.81, 124.17, 
126.03, 127.05, 130.91, 137.76, 141.24, 154.62, 157.79. MS (ESI+): m/z 444 [M+H]+. 
4-{5-[4-(2-Methoxy-benzyl)-piperazin-1-yl]-pentyloxy}-9H-carbazole (3). It was synthesized from 9 [15] 
(0.34 g, 1.02 mmol) and purified by flash chromatography. Elution with petroleum ether/CH2Cl2 /EtOH/ 
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ammonia solution 30% (7:2.5:0.5:0.025) afforded 3 as a solid: yield 57% ; mp 110-112 ºC; 1H NMR (200 
MHz, CDCl3) δ 1.61-1.64 (m, 4H), 1.96-1.99 (m, 2H), 2.37-2.40 (m, 2H), 2.57-2.66 (m, 8H), 3.67 (s, 2H), 
3.75 (s, 3H), 4.21 (t, J = 6.2 Hz, 2H), 6.65 (d, J = 7.4 Hz, 1H), 6.88-7.02 (m, 3H), 7.24-7.40 (m, 6H), 8.36 (d, 
J = 7.4 Hz, 1H), 8.92 (br s, 1H exchangeable with D2O). 13C NMR (100 MHz, CDCl3) δ 23.62, 25.36, 28.78, 
52.36 (2C), 53.98, 54.85, 55.16 (2C), 55.63, 67.22, 101.00, 103.23, 107.32, 109.87, 112.63, 119.54, 122.75, 
122.94 (2C), 123.56, 124.82, 125.69, 126.63, 129.58, 138.63, 140.87, 155.64, 156.79. MS (ESI+): m/z 458 
[M+H]+. 
4-{6-[4-(2-Methoxy-benzyl)-piperazin-1-yl]-hexyloxy}-9H-carbazole (4). It was synthesized from 10 [15] 
(0.35 g, 1.02 mmol) and purified by flash chromatography. Elution with: CH2Cl2/petroleum 
ether/EtOH/ammonia solution 30% (4:5.5:0.5:0.02) afforded 4 as a solid: yield 71% ; mp118-121 ºC; 1H 
NMR (400 MHz, DMSO-d6) δ 1.37-1.44 (m, 4H), 1.54-1.57 (m, 2H), 1.86-1.90 (m, 2H), 2.23-2.26 (m, 2H), 
2.57-2.67 (m, 8H), 3.33 (s, 2H), 3.74 (s, 3H), 4.16 (t, J = 6.2 Hz, 2H), 6.65 (d, J = 8 Hz, 1H), 6.89-6.95 (m, 
2H), 7.04 (d, J = 8 Hz, 1H), 7.11-7.14, (m, 1H), 7.16-7.19 (m, 1H), 7.25-7.33 (m, 3H), 7.42-7.44 (m, 1H), 
8.12 (d, J = 8 Hz, 1H), 11.06 (br s, 1H exchangeable with D2O). 13C NMR (100 MHz, DMSO-d6) δ 25.47, 
26.10, 26.47, 28.68, 52.62, 52.73, 55.10 (2C), 55.21, 57.63 (2C), 67.10, 100.21, 103.51, 110.22, 110.54, 
111.28, 118.37, 119.86, 121.59, 121.91, 124.29, 125.63, 126.32, 127.69, 129.50, 138,72, 140.91, 124.84, 
157.13. MS (ESI+): m/z 472 [M+H]+. 
4-{7-[4-(2-Methoxy-benzyl)-piperazin-1-yl]-eptyloxy}-9H-carbazole (5). It was synthesized from 11 (0.37 
g, 1.02 mmol) and purified by flash chromatography. Elution with petroleum ether/ethyl acetate/EtOH 
(7.16:2.5:0.34) afforded 5 as a solid: yield 52%; 1H NMR (400 MHz, CDCl3) δ 1.28-1.56 (m, 10H), 1.93 (t, J 
= 6.4 Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H),  2.51-2.61 (m, 6H), 3.62 (s, 2H), 3.72 (s, 3H), 4.17 (t, J = 6.4 Hz, 
2H), 6.61 (d, J = 8 Hz, 1H), 6.82 (d, J = 8 Hz, 1H), 6.92-6.94 (m, 2H), 7.22-7.34 (m, 6H), 8.31 (d, J = 8 Hz, 
1H), 8.89 (br s, 1H exchangeable with D2O). 13C NMR (100 MHz, CDCl3) δ 26.13, 26.44, 27.47, 29.23, 
29.36, 52.64 (2C), 52.88, 55.30 (2C), 56.10, 58.53, 67.80, 100.76, 103.40, 110.02, 110.50, 112.54, 119.29, 
120.27, 122.68, 122.93, 124.70, 125.48, 126.52, 128.36, 130.97, 138.84, 141.07, 155.68, 157.89. MS (ESI+): 
m/z 486 [M+H]+. 
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Biology 
 
Inhibition of AChE and BChE. The capacity of compounds 1-5 to inhibit human AChE and BChE activity 
was assessed using the Ellman’s assay [19]. A Jasco V-530 double beam spectrophotometer connected to 
HAAKE DC30 thermostating system (Thermo Haake, Germany) was used. Stock solutions of the tested 
compound (1 or 2 mM) were prepared in methanol and diluted in methanol. The assay solution consisted of a 
0.1 M phosphate buffer, pH 8.0, with the addition of 340 M 5,5’-dithiobis(2-nitrobenzoic acid), 0.02 
unit/mL human recombinant AChE or BChE from human serum (Sigma-Aldrich, Italy), and 550 M 
substrate, i.e., acetylthiocholine iodide (ACTh) or butyrylthiocholine iodide (BTCh), respectively (Sigma-
Aldrich, Italy). Test compounds were added to the assay solution at increasing concentrations and 
preincubated at 37°C with the enzyme for 20 min before the addition of substrate. The rate of absorbance 
increase at 412 nm was followed for 5 min. In parallel, blanks containing all components except the enzyme 
were prepared to account for the non enzymatic hydrolysis of the substrate. The reaction rates were 
compared and the percent inhibition due to the presence of test compounds was calculated. Each 
concentration was analyzed in duplicate/triplicate. The percent inhibition of the enzyme activity due to the 
presence of increasing concentrations of the compound was calculated. Inhibition plots were obtained for 
each compound by plotting the % inhibition versus the logarithm of inhibitor concentration in the assay 
solution. The linear regression parameters were determined for each curve and the IC50 extrapolated. 
Determination of the inhibitory effect on the A(1-42) self-aggregation [20]. To investigate the A(1-42) 
self-aggregation, a thioflavin T (ThT)-based fluorometric assay was performed. 1,1,1,3,3,3,-hexafluoro-2-
propanol-pretreated A(1-42) samples (Bachem AG, Germany) were resolubilized with a CH3CN/0.3 mM 
Na2CO3/250 mM NaOH (48.4:48.4:3.2) to have a stable stock solution ([A]=500 M). Experiments were 
performed by incubating the peptide in 10 mM phosphate buffer (pH 8.0) containing 10 mM NaCl at 30 °C 
for 24 h (final A = concentration 50 M) with and without the tested compound at 10 M. To quantify 
amyloid fibril formation, the thioflavin T fluorescence method was used [21, 22]. After incubation, the 
samples were diluted to a final volume of 2.0 mL with 50 mM glycine-NaOH buffer (pH 8.5) containing 1.5 
M ThT. A 300 s time scan of fluorescence intensity was carried out (exc = 446 nm, em = 490 nm), and 
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values at the plateau were averaged after subtraction of the background fluorescence of the 1.5 M ThT 
solution. 
 
Binding to nicotinic receptor subtypes. Frozen cortex and hippocampus specimens taken from adult male 
Sprague-Dawley rats (Charles River, Calco Italy) were homogenised using a Potter homogenizer in an 
excess of buffer A (50 mM Tris-HCl, pH 7, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 2.5 mM CaCl2 and 
2 mM phenylmethylsulfonyl fluoride), centrifuged (60 min at 30,000 x g), and rinsed twice. The 
homogenates were resuspended in the same buffer containing 20 g/ml of the protease inhibitors leupeptin, 
bestatin, pepstatin A, and aprotinin. 
[3H]-Epibatidine and [125I]--bungarotoxin binding to α4β2 cortical and α7 hippocampal  membrane-subtypes 
were per formed as previously described [23]. For [125I]--bungarotoxin, non-specific binding was 
determined in parallel by means of incubation in the presence of 1 M unlabelled -bungarotoxin and for 
[3H]-epibatidine, non-specific binding was determined by incubation with 10 nM epibatidine The inhibition 
of [3H]-epibatidine and [125I]--bungarotoxin binding by nicotine the compounds  was measured by 
incubating samples with increasing concentrations of each compound for five minutes followed by overnight 
incubation, at 4°C, with 0.1 nM [3H]-epibatidine (in the case of the α4β2 nAChR and at room temperature 
with 2 nM [125I]--bungarotoxin for the α7 nAChR subtype. After incubation, the membrane-bound α4β2 and  
α7 nAChR subtypes were washed five times with ice-cold PBS. [3H]-Epibatidine binding was determined by 
means of liquid scintillation counting in a β counter, and [125I]--bungarotoxin samples by direct counting in 
a  counter. 
The LIGAND program was used to calculate Ki values of all the tested compounds using data obtained from 
at least three independent saturation and competition binding experiments. 
 
Agonism of nAChRs. To test for agonism of α4β2 or α7 receptors, cRNAs encoding the receptor subunits 
were injected into defolliculated Xenopus oocytes. 50 nL of cRNA solution containing 100 ng/μL each of α4 
and β2 or α7 was injected into each oocyte and they were incubated for three days at 18 °C for protein 
expression to take place. The oocytes were then subjected to two-electrode voltage clamp using an 
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Axoclamp 2B (Axon Instruments, USA). Glass microelectrodes had a resistance of 0.5-1 MΩ when filled 
with 3 M KCl. The oocytes were clamped at -80 mV then ACh and compounds 1-5 were applied to the 
oocyte using an 8-channel perfusion system (Automate, USA). Currents were transferred to a PC and 
measured using Strathclyde Electrophysiology Software WinEDRv3.6.9. (Dr John Dempster, University of 
Strathclyde, UK). Currents in response to 1-5 were normalized to the response to ACh at the same 
concentration and in the same cell and plotted as % of ACh response ± SEM using Graphpad Prism 7.01. 
 
Computational Methods 
The docking simulations were performed using ICM 3.8 (Molsoft LLC, San Diego – CA, USA). The enzyme 
model was prepared starting from the crystallographic coordinates of the complex  formed by human AChE 
with fasciculin (PDBid: 1B41) [24] according to procedure reported in Belluti et al.[25]. Hydrogen atoms 
were added. Polar hydrogen atoms and the positions of asparagine and glutamine side chain amidic groups 
were optimized and assigned the lowest energy conformation. After optimization, histidines were assigned 
the tautomerization state which improved the hydrogen bonding pattern. Fasciculin was deleted and only the 
enzyme chain was retained. Ligands were built defining the right bond orders, stereochemistry, hydrogen 
atoms, and protonation states. Each ligand was assigned the MMFF force field atom types and charges [26]. 
The residues defining the binding pocket were selected according to the crystallographic poses of propidium 
in complex with the murine AChE (PDB code 1N5R) [27] and Donepezil (in complex with T. californica 
AChE, PDB code 1EVE) [28]. Sampling was performed using the Biased Probability Monte Carlo (BPMC) 
stochastic optimizer in an internal coordinate space as implemented in ICM [29]. Pre-calculated potential 
grid maps, representing Van der Waals potentials for hydrogens and heavier atoms, electrostatics, 
hydrophobicity, and hydrogen bonding, described the binding site. The adopted force field was a modified 
version of ECEPP/3 [30]. Based on the number of rotatable bonds in the ligand, the total number of BPMC 
steps to be carried out was calculated by an adaptive algorithm (thoroughness 1.0). The binding energy was 
assessed by means of the standard ICM empirical scoring function [31].  
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Results & discussion 
Compounds 1-5 were prepared following the synthetic procedures outlined in Figure 2. Nucleophilic 
substitution of the commercially available 6 with the opportune dibromo alkane gave intermediates 7-11 
according to the procedure reported in Rosini et al.[15]. 1-(2-methoxybenzyl)-piperazine (12), synthesized 
treating 1-cloromethyl-2-methoxybenzene with a large excess of piperazine, was then condensed with 
intermediates 7-11 under basic conditions to afford final compounds 1-5.  
 
 
Figure 2. Synthesis of 1-5. Reagents and conditions: (A) KOH, CH3CN; rt; (B) K2CO3, DMF; (C) K2CO3, 
DMF, N2, reflux. 
Initially, to determine the potential interest of compounds 1-5 as multifunctional agents for AD treatment, 
their AChE inhibitory activity was evaluated on human recombinant AChE by the method of Ellman and co-
workers [19]. The inhibitory activity towards BChE from human serum of 1-5 was also determined by the 
same assay. 
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Table 1 Inhibitory activity of human AChE and BChE, and amyloid aggregation by 1-5 and reference compounds.  
Compd n hAChE inhibition 
IC50 (M) ± SEMa 
hBChE inhibition 
IC50 (M) ± SEMa 
% inhibition 
of A 
self-induced 
aggregation ± 
SEMa b 
1 3 (2.12 ± 0.47) 10-4 (5.10 ± 0.38) 10-7 18.3 ± 0.8 
2 4 (3.19 ± 0.32) 10-5 (7.56 ± 0.19) 10-7 33.4 ± 0.1 
3 5 (2.39 ± 0.06) 10-6 (6.32 ± 0.31) 10-7 33.6 ± 0.1 
4 6 (7.73 ± 0.40) 10-7 (1.84 ± 0.06) 10-6 28.3 ± 1.1 
5 7 (5.01 ± 0.35) 10-4 (5.71 ± 0.22) 10-7 32.0 ± 2.0 
6 - nd nd 13.1 ± 2.0c 
Donepezil  - (2.31 ± 0.48) 10-8 (7.42 ± 0.39) 10-6 < 5 
Galantamine - (2.01 ± 0.15) 10-6d (2.07 ± 0.15) 10-5d < 5d 
Rivastigmine - (3.03 ± 0.21) 10-6d (3.01 ± 0.14) 10-7d 17.8 ± 1.6d 
a Human recombinant AChE and BChE from human serum were used. IC50 values represent the concentration of 
inhibitor required to decrease enzyme activity by 50% and are the mean of two independent measurements, each 
performed in duplicate; IC50 values were determined by Ellman’s method; SEM = standard error of the mean. b % 
inhibition of 50 µM Aβ(1–42) self-aggregation by 10 µM compound. The Aβ(1–42)/inhibitor ratio was equal to 5/1. 
Values are the mean of two independent experiments, each performed in duplicate; c from reference [15]; d from 
reference [32]; nd stands for not determined.  
 
As reported in Table 1, AChE inhibition was strictly dependent on the chain length separating the 
pharmacophoric functions. The most effective compounds were 4 (IC50 = 0.773 M) and, albeit to a lower 
extent, 3 (IC50 = 2.39 M), having a six and five methylene spacer, respectively, between the carbazole unit 
and the benzyl-piperazine moiety. Notably, inhibition of ACh cleavage by 3 was in line with that of current 
anticholinesterase drugs galantamine and rivastigmine (Table 1), while 4 performed slightly better. 
Conversely, shortening (1 and 2) or lengthening (5) the flexible tether resulted in an evident drop in activity. 
This behavior is typically related to a dual binding mode of inhibition [33-36], where a suitable chain length 
is determinant to allow compounds contacting the two recognition sites which distinguish the peculiar 
topology of AChE, namely internal and peripheral anionic sites [37].  
To verify this hypothesis and devise a structural explanation on how the length of the flexible linker 
modulates the AChE inhibitory potency of the synthesized compounds, docking simulations were performed 
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at the human AChE (hAChE) gorge by means of ICM3.8 (Molsoft LLC, San Diego, CA-USA) for 4 and its 
homologues 3 and 5. Donepezil (Figure 3A) and the inhibitor of the peripheral anionic site (PAS) propidium 
were used for comparison (Figure 3B).  
The model of the enzyme was based on the crystal structure of hAChE in complex with fasciculin (PDB 
code 1B41). The 4 hexyloxy spacer allows an optimal dual site interaction at both at the catalytic and at the 
PAS sites: a) the terminal benzyl group of the inhibitor establishes π - π interactions with Trp86; b) the 
protonated nitrogen atom can form a π - cation interaction with the side chain of Tyr337; and c) the carbazole 
group establishes π - π interactions with Trp286. Interestingly, when the predicted bound conformation of 4 
is compared to the known pose of donepezil (Figure 2A) it can be seen that it overlaps well (PBD code 
1EVE). Moreover, the carbazole nitrogen of 4 perfectly overlaps with the phenantridinic nitrogen of the 
propidium bound conformation (Figure 2B). Derivatives with shorter (3) and longer (5) linkers cannot be 
efficiently fitted in the binding pocket (Figure S1 and Figure S2 in Supporting Information). 
Concerning the inhibition of human BChE (hBChE), the length of the spacer did not significantly influence 
the inhibitory profile, as all the compounds presented similar inhibitory values in the micromolar range 
(Table 1). Interestingly, this resulted in a balanced dual AChE/BChE inhibitory potency for 3 and 4.With 
better understanding of the inter-relationship of AChE and BChE in the AD brain, this balanced action may 
have potential therapeutic benefits, as both enzymes are recognized therapeutic targets at different stages of 
the pathology.  Indeed, as AD evolves, the activity of AChE decreases while that of BChE increases [5], in 
an attempt to modulate ACh levels in cholinergic neurons. Therefore, the synergistic inhibition of both 
cholinesterase (ChE) enzymes might be a more valuable approach for the moderate form of the AD. 
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Figure 3. The bound conformation of 4 at the binding site of hAChE predicted by docking simulations. The 
ligand is reported in orange x-sticks. The key residues of the binding pocket are reported in light grey x-sticks and 
labelled explicitly. The rest of the protein is described by a transparent pink cartoon representation. A transparent white 
mesh describes the boundaries of the binding pocket. (A) The overlap between 4 and donepezil crystallographic pose 
(light green x-sticks, PDB CODE: 1EVE). (B) The overlap between 4 and propidium crystallographic pose (dark green 
x-sticks, PDB CODE: 1N5R) 
As a part of our multitarget project, we sought to verify if anti-ChE activity of compounds 1-5 could be 
accompanied by effective nAChR activation, as we envisioned the weak perturbation of different ACh-
mediated targets as a valuable strategy to gain potential additive or synergistic enhancement of cholinergic 
neurotransmission.  
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Table 2 Binding affinity (Ki, nM) of compounds 1-5 to α4β2 and α7 rat nicotinic receptor subtypes, labelled with [3H]-
epibatidine and [125I]-α-bungarotoxin, respectivelya. 
Compd N Ki, µM (%CV) 
α4β2 
Ki, µM (%CV) 
α7 
1 3 22.70 (22) 29.20 (50) 
2 4 44.00 (18) 15.20 (62) 
3 5 66.80 (21) 35.30 (72) 
4 6 90.00 (19) 120.00 (69) 
5 7 61.20 (21) 72.90 (57) 
a The Ki values were derived from [3H]-epibatidine and [125I]--bungarotoxin saturation and three competition binding 
experiments on  cortical and hippocampal rat brain membranes The curves were fitted using a nonlinear least squares 
analysis program and the F test. The numbers in brackets represent the % coefficient of variation (CV). 
 
Therefore, preliminary binding assays were carried out to assess whether compounds 1-5 could displace 
[3H]-epibatidine and [125I]-α-bungarotoxin from α4β2 and α7 receptor subtypes of rat cortex, respectively 
(Table 2). All of the compounds presented a micromolar affinity profile with Ki values ranging from 15 to 
120 µM, without discriminating the receptor subtypes. The binding affinity to nAChRs seemed to be 
influenced by the chain length separating the pharmacophoric functions, even though, unfortunately, an 
inverted trend of efficacy was observed compared to AChE inhibition, with compound 4 the less efficacious 
at both receptor subtypes. The Ki values determined by binding studies do not allow comparison between the 
nicotinic efficacies of 1-5 and galantamine, for which a sensitizing action on nAChRs by allosteric (and not 
ortosteric) modulation of the α4β2 and α7 subtypes has been proposed to complement cholinesterase 
inhibition [38]. 
To substantiate the mode of action toward nAChRs, we also tested synthesised compounds on α4β2 and α7 
nAChRs subtypes, heterologously expressed in Xenopus oocytes by using two-electrode voltage clamp. 
Membrane potential was clamped at -80 mV and, to evaluate the activity of compounds 1-5, they were 
applied at two different concentrations (10 and 100 µM) in comparison with the agonist ACh.  
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Figure 4. Responses of α4β2 to 1-5 (100 µM). 1-5 at a concentration of 100 μM were applied to Xenopus 
oocytes clamped at -80 mV and their responses normalised to that of 100 μM ACh in the same cell (n = 5-8). 
Inset: Current responses to 100 μM ACh (blue) and 100 μM 5 (red) on the same oocyte expressing α4β2. The 
black bar indicates application of the agonist. 
 
While a negligible effect was detected at 10 μM concentration (see Table S1 in Supporting Information), a 
weak activation on membrane current for the α4β2 receptor subtype was observed at 100 µM for all 
compounds, ranging from 15 to 22% of the response to 100 μM ACh (Figure 4). Conversely, no responses 
could be detected on α7 nAChR, probably because this receptor subtype has a lower sensitivity to ACh [39] 
or because of the fast desensitization which could considerably complicate the ion current measurements. 
Low levels of persistent activation of α4β2 receptors may be beneficial in terms of improving the excitability 
of postsynaptic neurons or enhancing neurotransmitter release presynaptically. 
Finally, to disclose the proposed dual interventions on cholinergic and amyloidogenic pathways, the ability 
of compounds 1-5 towards the inhibition of Aβ(1-42) self-aggregation was investigated. The carbazole 
building block (6) was also included in the study to clarify the role of this fragment. A ThT-based 
fluorimetric assay was used to quantify Aβ fibril formation in the presence and absence of inhibitor 
(Aβ/inhibitor ratio 5/1). Data in Table 1 show that all compounds at 10 µM  concentration inhibited Aβ(1-42) 
self-aggregation, with inhibition by 2-5  ranging from 28 to 36%, similarly to the known anti-aggregating 
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compound curcumin (34.4±1.1%, at 10 µM)[40]. The observed efficacies are significantly higher with 
respect to the carbazole moiety alone, corroborating the importance of substitution for boosting the inhibitory 
capability towards A assembly. 
Interestingly, any of the marketed AChEIs, including galantamine, display significant high antiaggregating 
ability (Table 1). Consequently, these new compounds propose an expanded multitarget profile for AChEIs, 
through the incorporation of additional and mutual interconnected anti-AD properties.  
 
Conclusion 
The multifactorial nature of AD is a critical issue which hampers the discovery of effective disease 
modifying therapies. In this light, multitarget compounds have recently been proposed to address 
simultaneously multiple targets critically involved in the AD network [41]. By exploiting this approach, the 
present study provided compounds 3 and 4 which presented a moderate-affinity profile against all the 
selected targets. Particularly, a low but significant activation of α4β2 nAChRs (15-20% at 100 µM) was 
combined to a micromolar AChE inhibitory profile. This latter activity is not dissimilar to that of some of the 
current marketed drugs. What’s more, the ability to reduce Aβ self-aggregation shown by 3 and 4 at 10 µM 
makes them very interesting starting points for further development. In fact, when two or more targets are 
interconnected, as for cholinergic neurotransmission (AChE, nAChRs) and amyloid, a weak perturbation of 
one or both partner systems might be sufficient to accomplish a significant modification of the whole 
scenario, in a synergistic way. Furthermore, the mild but multiple perturbation might prevent unwanted 
compensatory mechanisms that are typical of high-affinity single target compounds [42].  
Future perspectives 
Despite the opportunities conceptually offered by the multitarget drug-design strategy and the enthusiasm 
generated around it, the effective development of multitarget drugs is extremely challenging. Indeed, the 
generation of a valuable multitarget drug is a compromise and balance iterative process. 
From the start, selection of the targets is fundamental to establish whether their modulation could lead to 
additive effects or synergistic potentiation [43]. Herein, we envisaged the simultaneous modulation of human 
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ChE and nAChRs as a suitable tool to synergistically turn up the cholinergic transmission, which is impaired 
in AD. More interestingly, based on the widely recognized cross-talk between nAChRs and the Aβ pathway, 
we proposed nAChR activation as a crucial tether between the symptomatic relief of cholinergic potentiation 
and the neuroprotective prospects of antiaggregating agents. Thus, by intervening on the three pathways, we 
aim to synergistically interfere with crucial points of recognized AD pathogenic players. Aware of the work 
still to be done in terms of potency, affinity-balancing and developing α7 agonism, we believe that these new 
compounds may represent a starting point for a further optimization process. We are also confident that our 
rationale may offer a valuable input towards translating the findings of network medicine into clinically 
actionable tools. 
 
 
 
Executive summary 
 AD has a multifactorial nature, with a network of simultaneous and synergistic processes. 
 The rational design of single chemical entities addressing multiple targets is a promising and 
challenging strategy, with higher beneficial impact to confront AD. 
 Selection of the targets is crucial to achieve additive effects or synergistic potentiation. 
 The amyloidogenic and cholinergic pathways, while being considered independent for years, 
share a number of molecular features that merge at several points. 
 The present study provides new molecules able to potentiate the cholinergic neurotransmission, 
by combining direct nicotinic receptor activation to acetylcholinesterase inhibition, and to inhibit 
Aβ aggregation. 
 The obtained results offer a valuable input for a further optimization process. 
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